Proposed are studies of the duration of buprenorphine blockade of the effects of challenge doses of hydromorphone. These studies build on the investigator's published finding that blockade of exogenous hydromorphone effects by buprenorphine appears to last for at least three days. The initial proposed studies will involve sequential, randomized, single- blind discontinuation of active buprenorphine for 1, 3, 5, or 7 days in buprenorphine-dependent patients. At the end of these discontinuation periods, addicts will be challenged with intramuscular hydronorphone to assess the extent of blockade present. A proposed follow-up study extends the study of duration of buprenorphine blockade to blockade by single doses of buprenorphine in subjects who are not opiate dependent. Plasma buprenorphine levels will be collected in each of the above studies 1, 6, and 24 hours after the last buprenorphine dose, and immediately before the hydromorphone challenges. Across-subject comparisons will allow us to determine whether inter-individual differences have a pharmacokinetic basis. The studies will define the relationship, if there is any, between (drug exposure) plasma levels and duration of buprenorphine's actions. The proposed research might suggest innovative buprenorphine dosing schedules. A careful description concomitantly of the clinical phenomena of buprenorphine blockade, withdrawal, and plasma levels is proposed.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA009250-05
Application #
6104093
Study Section
Project Start
1998-09-30
Project End
1999-09-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
5
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Chawarski, Marek C; Fiellin, David A; O'Connor, Patrick G et al. (2007) Utility of sweat patch testing for drug use monitoring in outpatient treatment for opiate dependence. J Subst Abuse Treat 33:411-5
Chawarski, Marek C; Moody, David E; Pakes, Juliana et al. (2005) Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms. J Subst Abuse Treat 29:307-12
Kosten, Thomas R; Fiellin, David A; U.S. National Buprenorphine Implementation Program (2004) Buprenorphine for office-based practice: consensus conference overview. Am J Addict 13 Suppl 1:S1-7
Kosten, Thomas; Oliveto, Alison; Feingold, Alan et al. (2003) Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend 70:315-25
Sofuoglu, Mehmet; Gonzalez, Gerardo; Poling, James et al. (2003) Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence. Am J Drug Alcohol Abuse 29:713-27
Kosten, Thomas; Poling, James; Oliveto, Alison (2003) Effects of reducing contingency management values on heroin and cocaine use for buprenorphine- and desipramine-treated patients. Addiction 98:665-71
Stine, Susan M; Southwick, Steven M; Petrakis, Ismene L et al. (2002) Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. Biol Psychiatry 51:642-51
Stine, S M; Grillon, C G; Morgan 3rd, C A et al. (2001) Methadone patients exhibit increased startle and cortisol response after intravenous yohimbine. Psychopharmacology (Berl) 154:274-81
Jacobsen, L K; Southwick, S M; Kosten, T R (2001) Substance use disorders in patients with posttraumatic stress disorder: a review of the literature. Am J Psychiatry 158:1184-90
Gottschalk, C; Beauvais, J; Hart, R et al. (2001) Cognitive function and cerebral perfusion during cocaine abstinence. Am J Psychiatry 158:540-5

Showing the most recent 10 out of 39 publications